Ellen Stacy Rosenberg

General Counsel & Corporate Secretary at Amicus Therapeutics, Inc.

Ellen Stacy Rosenberg

Ellen Stacy Rosenberg

General Counsel & Corporate Secretary at Amicus Therapeutics, Inc.

Overview
Career Highlights

Amicus Therapeutics, Inc.

RelSci Relationships

196

Birthday

1963

Age

55

Relationships
RelSci Relationships are individuals Ellen Stacy Rosenberg likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Senior Vice President at E. R. Squibb & Sons Inter-American Corp.

Relationship likelihood: Strong

Chief Financial & Business Officer at Rapid Micro Biosystems, Inc.

Relationship likelihood: Strong

Partner at Wilson Sonsini Goodrich & Rosati PC

Relationship likelihood: Strong

Partner at Wilson Sonsini Goodrich & Rosati PC

Relationship likelihood: Strong

Former President & Chief Operating Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Former Chief Financial Officer & Secretary at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Chief Compliance Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Chief Science Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Average

Chief Medical Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Average

Paths to Ellen Stacy Rosenberg
Potential Connections via
Relationship Science
You
Ellen Stacy Rosenberg
General Counsel & Corporate Secretary at Amicus Therapeutics, Inc.
Education

The University of Pennsylvania Law School, located in Philadelphia, Pennsylvania, is the law school of the University of Pennsylvania. A member of the Ivy League, it is among the oldest and most selective law schools in the nation. It is currently ranked 7th overall by U.S. News & World Report, and 1st in terms of career prospects by the Princeton Review, a rank awarded also by the National Law Journal based on placement of graduates in top law firms.It offers the degrees of Juris Doctor (J.D.), Master of Laws (LL.M.), Master of Comparative Laws (LL.C.M.), and Doctor of the Science of Law (S.J.D.).

The University of Connecticut (UConn) is a public research university in Connecticut. Known as a Public Ivy,[3] UConn was founded in 1881 and is a Land Grant and Sea Grant college & member of the Space Grant Consortium. The institution serves more than 30,000 students on its six campuses, including more than 8,000 graduate students in multiple programs.[4] UConn's main campus is in Storrs, Connecticut. The university's president is Susan Herbst.[5] UConn is one of the founding institutions of the Hartford, Connecticut/Springfield, Massachusetts regional economic and cultural partnership alliance known as New England's Knowledge Corridor. UConn is a member of Universitas 21, a global network of 24 research-intensive universities, who work together to foster global citizenship and institutional innovation through research-inspired teaching and learning, student mobility, connecting students and staff, and promote advocacy for internationalisation.[6] UConn is accredited by the New England Association of Schools and Colleges.

Career History
General Counsel & Corporate Secretary
2016 - Current

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Secretary
2015 - Prior

NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company's lead clinical programs involve two proprietary therapeutic peptides to restore or replace biological function: Gattex® (teduglutide) and Natpara® (recombinant human parathyroid hormone (rhPTH 1-84)). NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia and hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceuticals.

Secretary & Senior Vice President
Prior

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs. We focus on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including disease caused by C1 esterase inhibitor deficiency and C. difficile. In everything we do, throughout our organization, we are committed to patient and physician needs, as we work to bring new products to markets with few, if any, therapeutic options. We are dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.

Transactions
Details Hidden

Amicus Therapeutics, Inc. issued Common Stock

Details Hidden

Amicus Therapeutics, Inc. purchases MiaMed, Inc.

Details Hidden

Amicus Therapeutics, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations